drugset / Trial / NCT01320033

Placebo Controlled Efficacy and Safety Study of CD2475/101 40 mg Tablets vs. Placebo and Doxycycline 100 mg Capsules Once Daily in the Treatment of Inflammatory Lesions of Acne Vulgaris

NCT01320033

Phase 2 Completed 662 enrolled Galderma R&D
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objectives of the study is to show CD2475/101 40mg tablets taken once a day for 16 weeks is superior to the placebo in Change from baseline to Week 16(Last Observation Carry Forward, Intent To Treat) in inflammatory lesion counts.

Timeline

Start
2011-03-29
Primary completion
2012-01-03
Completion
2012-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CD2475/101 Unknown 40 mg Oral
Comparator Doxycycline Small molecule 100 mg Oral

Indications